Compare Torrent Pharma with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs CADILA HEALTHCARE - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA CADILA HEALTHCARE TORRENT PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 38.4 35.4 108.4% View Chart
P/BV x 9.7 6.2 156.6% View Chart
Dividend Yield % 0.6 0.6 112.7%  

Financials

 TORRENT PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-19
CADILA HEALTHCARE
Mar-20
TORRENT PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,964352 557.5%   
Low Rs1,245207 602.9%   
Sales per share (Unadj.) Rs453.4139.2 325.7%  
Earnings per share (Unadj.) Rs25.811.8 219.2%  
Cash flow per share (Unadj.) Rs62.318.6 335.4%  
Dividends per share (Unadj.) Rs17.003.50 485.7%  
Dividend yield (eoy) %1.11.3 84.6%  
Book value per share (Unadj.) Rs279.2101.4 275.5%  
Shares outstanding (eoy) m169.221,023.74 16.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.52.0 176.3%   
Avg P/E ratio x62.223.7 262.0%  
P/CF ratio (eoy) x25.815.0 171.2%  
Price / Book Value ratio x5.72.8 208.5%  
Dividend payout %65.929.8 221.6%   
Avg Mkt Cap Rs m271,513286,033 94.9%   
No. of employees `00013.613.4 101.4%   
Total wages/salary Rs m14,03824,145 58.1%   
Avg. sales/employee Rs Th5,642.610,632.7 53.1%   
Avg. wages/employee Rs Th1,032.41,801.2 57.3%   
Avg. net profit/employee Rs Th320.9898.5 35.7%   
INCOME DATA
Net Sales Rs m76,728142,531 53.8%  
Other income Rs m5711,139 50.1%   
Total revenues Rs m77,299143,670 53.8%   
Gross profit Rs m19,83124,198 82.0%  
Depreciation Rs m6,1776,965 88.7%   
Interest Rs m5,0383,418 147.4%   
Profit before tax Rs m9,18714,954 61.4%   
Minority Interest Rs m0288 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5700-   
Tax Rs m1,2543,198 39.2%   
Profit after tax Rs m4,36312,044 36.2%  
Gross profit margin %25.817.0 152.2%  
Effective tax rate %13.621.4 63.8%   
Net profit margin %5.78.5 67.3%  
BALANCE SHEET DATA
Current assets Rs m50,37587,154 57.8%   
Current liabilities Rs m51,65382,694 62.5%   
Net working cap to sales %-1.73.1 -53.2%  
Current ratio x1.01.1 92.5%  
Inventory Days Days9271 128.9%  
Debtors Days Days6894 72.8%  
Net fixed assets Rs m83,648133,236 62.8%   
Share capital Rs m8461,024 82.6%   
"Free" reserves Rs m46,397102,733 45.2%   
Net worth Rs m47,244103,757 45.5%   
Long term debt Rs m39,12932,146 121.7%   
Total assets Rs m141,209236,866 59.6%  
Interest coverage x2.85.4 52.5%   
Debt to equity ratio x0.80.3 267.3%  
Sales to assets ratio x0.50.6 90.3%   
Return on assets %6.76.5 102.0%  
Return on equity %9.211.6 79.6%  
Return on capital %12.313.7 89.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m22,10352,752 41.9%   
Fx outflow Rs m5,52214,504 38.1%   
Net fx Rs m16,58138,248 43.4%   
CASH FLOW
From Operations Rs m17,98125,054 71.8%  
From Investments Rs m-2,413-10,123 23.8%  
From Financial Activity Rs m-13,145-10,942 120.1%  
Net Cashflow Rs m2,3803,989 59.7%  

Share Holding

Indian Promoters % 71.5 74.8 95.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 8.3 84.6%  
FIIs % 12.6 5.9 213.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 11.0 80.0%  
Shareholders   26,511 44,069 60.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   DIVIS LABORATORIES  GLENMARK PHARMA  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Snap 4-Day Winning Streak; JSW Steel and Hindalco Among Top Losers(Closing)

Indian share markets witnessed selling pressure throughout the day today and ended lower.

Related Views on News

AUROBINDO PHARMA at All Time High; BSE HEALTHCARE Index Up 0.7% (Market Updates)

May 11, 2021 | Updated on May 11, 2021

AUROBINDO PHARMA share price has hit an all time high at Rs 1,064 (up 1.4%). The BSE HEALTHCARE Index is up by 0.7%. Among the top gainers in the BSE HEALTHCARE Index today are AUROBINDO PHARMA (up 1.4%) and PFIZER (up 1.4%). The top losers include PIRAMAL ENTERPRISES and CAPLIN POINT (down 0.2%).

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


May 11, 2021 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS